Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial

被引：0
作者：
Taoping Weng
Feng Sun
Yang Li
Jiazhen Chen
Xinchang Chen
Rong Li
Shijia Ge
Yanlin Zhao
Wenhong Zhang
机构：
[1] Huashan Hospital,Departments of Infectious Diseases
[2] Fudan University,National Center for Tuberculosis Control and Prevention
[3] Chinese Center for Disease Control and Prevention,undefined
来源：
BMC Infectious Diseases | / 21卷
关键词：
Tuberculosis; Multidrug-resistant tuberculosis; Multicenter; Randomized trial; Non-inferiority; Precision treatments; Ultra-short regimen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 138 条
  • [1] Cox H(2018)Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible? Lancet Infect Dis 18 e282-e287
  • [2] Hughes J(2010)Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis Am J Respir Crit Care Med 182 684-692
  • [3] Black J(2015)High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 19 517-524
  • [4] Nicol MP(2014)High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 18 1188-1194
  • [5] Van Deun A(2019)A trial of a shorter regimen for rifampin-resistant tuberculosis N Engl J Med 380 1201-1213
  • [6] Maug AKJ(2020)Treatment of Highly Drug-Resistant Pulmonary Tuberculosis N Engl J Med 382 893-902
  • [7] Salim MAH(2019)Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study Eur Respir J 53 1801770-1016.e5
  • [8] Das PK(2017)A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide Nat Commun 8 588-8
  • [9] Sarker MR(2018)Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Clin Microbiol Infect 24 1016.e1-2510
  • [10] Daru P(2019) clinical isolates in Hangzhou, China Front Microbiol 10 1741-5
12345678910